Navigation Links
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Date:2/24/2011

news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Alere Inc. ... rapid diagnostics, issued the following statement today in support ... Antibiotic-Resistant Bacteria. "As the global leader in ... for establishing a national strategy to address the serious ... to work with the Administration on initiatives to promote ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
(Date:9/19/2014)... 2014 Reductions in kidney failure ... in people with diabetes type 2 "Intensive ... for the kidneys." Australian researchers have discovered ... diabetes leads to persistent reductions in kidney failure many ... global study has found that, five and a half ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... , BETHESDA, Md. , ... CHDX ), a leading independent American provider of Western,healthcare products and ... the Company plans to release third quarter fiscal year 2010,financial results ... will host a conference call at 8:00 am ET ...
... , RICHMOND, Calif. , ... announced that the company will release its fourth quarter and full year ... market closes. The press release will be followed by a conference call ... public via telephone and webcast. During the conference call, the company will ...
Cached Medicine Technology:Chindex International to Report Third Quarter Fiscal Year 2010 Financial Results 2Chindex International to Report Third Quarter Fiscal Year 2010 Financial Results 3Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast 2
(Date:9/20/2014)... (PRWEB) September 20, 2014 The festival season ... busy selling its newly released luxurious cocktail dresses . ... company has recently decided to launch a new promotion for ... is offered with a discounted price, from 20 to 71 ... a wide range of choices. They are provided in many ...
(Date:9/20/2014)... September 20, 2014 New PharmaPoint ... Market Analysis to 2023?. The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ...
(Date:9/20/2014)... the popular online supplier of wedding dresses and special ... collection of cocktail gowns. This afternoon, the company announced ... outfits; it intends to expand its online market in ... cocktail dresses in the company’s online store. ... experience in the industry of women’s special occasion dresses. ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The excitement is building ... Mount Airy, North Carolina. This year the Surry Arts Council ... people from around the country who are still fans of the ... is a sitcom that aired on CBS from 1960 through 1968. ... show in American television history. Mount Airy, North Carolina is ...
(Date:9/20/2014)... September 20, 2014 "As a nurse, patients ... tanks," said an inventor from Tamaqua, Pa. "The reason that ... the backs of their chairs. My invention enables them to ... Kam Oxygen Sensor to make it easier to monitor the ... user knows when the tank is low. It allows changeovers ...
Breaking Medicine News(10 mins):Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2
... and high-school students who bully their classmates are more likely ... marijuana, a new study found. Researchers found that bullies ... were more likely to use substances than were victims ... behavior may be related to another," said Kisha Radliff, lead ...
... (March 5, 2012) Chinese Minister of Health, Dr. Zhu ... researchers from across the U.S. and China with the goal ... and creating deeper ties to fast-track cancer research. The ... renowned cancer experts, designed to develop a framework for future ...
... -- Vitamin E may stimulate cells that result in ... by Shu Takeda of Keio University in Tokyo said ... vitamin E supplements. The researchers explain that maintaining ... (osteoclasts) keeps bones strong. Although prior studies had suggested ...
... , MONDAY, March 5 (HealthDay News) -- Babies ... greater risk of developing asthma when compared with children born ... to infants born between the 34th and 37th week of ... an asthma diagnosis by the age of 8 years, despite ...
... March 2012: Each year over 4.3 million people ... yet many of these deaths might have been prevented ... smoking cessation, weight loss, improved diets and increased ... interventions will be presented, together with cutting-edge research on ...
... Fla. Researchers have identified a gene that causes adult-onset ... twist involuntarily. The discovery by a team from the Jacksonville, ... Health Sciences Center sheds light on a movement disorder that ... Annals of Neurology . In 1990, ...
Cached Medicine News:Health News:School bullies more likely to be substance users, study finds 2Health News:School bullies more likely to be substance users, study finds 3Health News:Chinese Minister of Health to hold US meeting to improve cancer research collaboration 2Health News:Mouse Study Suggests Vitamin E May Weaken Bones 2Health News:Late Preemie Birth May Be Linked to Higher Asthma Risk 2Health News:EuroPRevent2012, the premier international forum for preventive cardiology 2Health News:EuroPRevent2012, the premier international forum for preventive cardiology 3Health News:EuroPRevent2012, the premier international forum for preventive cardiology 4Health News:EuroPRevent2012, the premier international forum for preventive cardiology 5Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 2Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 3
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Medicine Products: